Leerink Partnrs Comments on Immunovant, Inc.’s Q1 2025 Earnings (NASDAQ:IMVT)

Immunovant, Inc. (NASDAQ:IMVTFree Report) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Immunovant in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($0.42) per share for the quarter. The consensus estimate for Immunovant’s current full-year earnings is ($1.83) per share. Leerink Partnrs also issued estimates for Immunovant’s FY2026 earnings at ($2.23) EPS, FY2027 earnings at ($2.28) EPS and FY2028 earnings at ($1.57) EPS.

Immunovant (NASDAQ:IMVTGet Free Report) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.45) earnings per share for the quarter, meeting the consensus estimate of ($0.45).

Several other research firms have also issued reports on IMVT. Piper Sandler raised their price target on Immunovant from $28.00 to $57.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 24th. HC Wainwright lifted their price objective on shares of Immunovant from $47.00 to $51.00 and gave the stock a “buy” rating in a research note on Thursday, December 21st. Truist Financial upped their target price on shares of Immunovant from $30.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, November 15th. UBS Group lifted their price target on shares of Immunovant from $55.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, December 1st. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Immunovant in a report on Tuesday, December 12th. They issued a “buy” rating and a $50.00 price target for the company. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $46.92.

View Our Latest Analysis on IMVT

Immunovant Stock Performance

IMVT opened at $35.27 on Wednesday. The company has a fifty day moving average price of $40.27 and a two-hundred day moving average price of $32.62. The firm has a market capitalization of $5.10 billion, a PE ratio of -17.90 and a beta of 0.70. Immunovant has a 52 week low of $14.05 and a 52 week high of $45.58.

Institutional Investors Weigh In On Immunovant

Institutional investors and hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC bought a new stake in shares of Immunovant during the 4th quarter worth $27,000. Comerica Bank bought a new position in shares of Immunovant in the 3rd quarter valued at $26,000. Barclays PLC boosted its holdings in shares of Immunovant by 2,558.1% during the 2nd quarter. Barclays PLC now owns 2,286 shares of the company’s stock valued at $43,000 after acquiring an additional 2,200 shares in the last quarter. Metropolitan Life Insurance Co NY grew its position in Immunovant by 24.7% during the 2nd quarter. Metropolitan Life Insurance Co NY now owns 2,951 shares of the company’s stock worth $56,000 after acquiring an additional 585 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Immunovant by 96.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,360 shares of the company’s stock worth $129,000 after acquiring an additional 1,651 shares during the last quarter. Institutional investors own 42.45% of the company’s stock.

Insider Activity at Immunovant

In other news, CFO Eva Renee Barnett sold 3,515 shares of the business’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $41.83, for a total transaction of $147,032.45. Following the transaction, the chief financial officer now directly owns 323,350 shares in the company, valued at approximately $13,525,730.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Julia G. Butchko sold 1,297 shares of the business’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $38.59, for a total value of $50,051.23. Following the completion of the sale, the insider now owns 409,963 shares of the company’s stock, valued at $15,820,472.17. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Eva Renee Barnett sold 3,515 shares of Immunovant stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $41.83, for a total transaction of $147,032.45. Following the completion of the sale, the chief financial officer now owns 323,350 shares of the company’s stock, valued at $13,525,730.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,624 shares of company stock valued at $1,248,375. 4.80% of the stock is owned by corporate insiders.

About Immunovant

(Get Free Report)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.

See Also

Earnings History and Estimates for Immunovant (NASDAQ:IMVT)

Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.